Skip to content
value.today

Verve Therapeutics, Inc.

Total raised
$94 M
1 round on record
Latest round
$94 M
Jan 2021
First round on record
Jan 2021
Today
Acquired
Acquired by Eli Lilly and Company

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Verve Therapeutics, Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Verve Therapeutics, IncEli Lilly and Company2025—$549 M—Annual report

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Verve Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2021$94 MNo. 1$50 to $250 million

Verve Therapeutics, Inc.: Raise no. 1, Jan 2021

Investors in this round

22 investors had bought by the notice of Jan 22, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 26 investors are named for Verve Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$94 M of $94 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Ashe · Executive Officer
  • Andrew Bellinger · Executive Officer
  • Sekar Kathiresan · Executive Officer, Director
  • Anthony Philippakis · Director
  • Burt Adelman · Director
  • John Evans · Director
  • Krishna Yeshwant · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Ashe, President and Chief Operating Officer. Source: SEC Form D, newest notice filed Jan 22, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Verve Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).

    SEC Form D · Jan 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2021

That is all the official record says: Verve Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

26 named in official filings. Open an investor to see everything it has backed.

Investors in Verve Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
ARCH Venture Fund X, L.P.Venture capitalnot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Fund X Overage, L.P.Venture capitalnot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X, LLCVenture capitalnot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners X Overage, L.P.Venture capitalnot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Beam Therapeutics Inc.Companynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Biomatics Capital Partners, L.P.Fund or asset managernot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Casdin Partners Master Fund, L.P.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Casdin Private Growth Equity Fund, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Fmr LLCFund or asset managernot statednot statedHeld Series A and A-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2017 GP, L.L.C.Othernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2017 GP, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2017, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2019 GP, L.L.C.Othernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2019 GP, L.P.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2019, L.P.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Logos Global Management LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Rock Springs Capital LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Rock Springs Capital Management LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Rock Springs Capital Master Fund LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Verve Therapeutics, Inc.
NameRoleNamed in
Andrew AsheExecutive officerJan 2021
Andrew BellingerExecutive officerJan 2021
Sekar KathiresanExecutive officerJan 2021
Anthony PhilippakisDirectorJan 2021
Burt AdelmanDirectorJan 2021
John EvansDirectorJan 2021
Krishna YeshwantDirectorJan 2021
Sekar KathiresanDirectorJan 2021

Acquired (Jan 1, 2025). Acquired by Eli Lilly and Company.